Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the Uni…
Biotechnology
US, Cambridge [HQ]
Cash Flow Statements
8 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Cash Flow (OCF) | 66.00 | -331.00 | -330.00 | -458.00 | 2,026.00 | 13,620.00 | 4,981.00 | -3,118.00 | |
| Operating Cash (Net) | 66.00 | -331.00 | -330.00 | -458.00 | 2,026.00 | 13,620.00 | 4,981.00 | -3,118.00 | |
| Accounts Receivable | 52.00 | - - | - - | 7.00 | -1,385.00 | -1,784.00 | 1,790.00 | 493.00 | |
| Accounts Payable | 5.00 | -12.00 | 15.00 | -23.00 | 11.00 | 204.00 | 240.00 | 13.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Change | 225.00 | -137.00 | -42.00 | -53.00 | 2,577.00 | 990.00 | -3,455.00 | -139.00 | |
| Other WC | 168.00 | -159.00 | -62.00 | -44.00 | 3,996.00 | 3,964.00 | -5,977.00 | -1,392.00 | |
| Investing Activities | |||||||||
| Used Cash (Net) | -648.00 | 416.00 | -372.00 | -14.00 | -1,671.00 | -8,523.00 | -5,176.00 | 4,206.00 | |
| Capital Expenditure | -33.00 | -58.00 | -105.00 | -31.00 | -67.00 | -284.00 | -400.00 | -707.00 | |
| Purchases of Investments | -1,415.00 | -727.00 | -1,227.00 | -1,145.00 | -2,956.00 | -12,652.00 | -11,435.00 | -3,760.00 | |
| Sale/Maturity of Investment | 808.00 | 1,202.00 | 960.00 | 1,161.00 | 1,351.00 | 4,443.00 | 6,699.00 | 8,781.00 | |
| Property, Plant, Equipment (P&PE) | -33.00 | -58.00 | -105.00 | -31.00 | -67.00 | -284.00 | -400.00 | -707.00 | |
| Acquisitions (Net) | - - | - - | - - | -17.00 | 1,604.00 | - - | - - | -85.00 | |
| Other Investing Activities | -8.00 | -1.00 | - - | 17.00 | -1,604.00 | -30.00 | -40.00 | -23.00 | |
| Financing Activities | |||||||||
| Used Cash (Net) | -472.00 | - - | -1,226.00 | -51.00 | -2,033.00 | -873.00 | -3,448.00 | -1,377.00 | |
| Debt Repayment | - - | -1.00 | -2.00 | -1.00 | -6.00 | -140.00 | -184.00 | -270.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | 571 | 44 | 1,845 | 981 | 3,394 | 1,199 | |
| Issued | 473.00 | - - | 563.00 | 47.00 | 1,852.00 | 124.00 | 65.00 | 46.00 | |
| Repurchased | - - | - - | -8.00 | 2.00 | 7.00 | -857.00 | -3,329.00 | -1,153.00 | |
| Other Financing Activities | 472.00 | - - | 674.00 | - - | 186.00 | 124.00 | 184.00 | 270.00 | |
| Cash Balances | |||||||||
| Begin of Period | 159.00 | 50.00 | 134.00 | 670.00 | 247.00 | 2,636.00 | 6,860.00 | 3,217.00 | |
| End of Period | 50.00 | 134.00 | 658.00 | 247.00 | 2,635.00 | 6,860.00 | 3,217.00 | 2,928.00 | |
| Change | -108.00 | 84.00 | 523.00 | -422.00 | 2,388.00 | 4,224.00 | -3,643.00 | -289.00 | |
| Non-Cash Balances | |||||||||
| Depreciation and Amortization | 15.00 | 20.00 | 24.00 | 31.00 | 31.00 | 232.00 | 348.00 | 621.00 | |
| Stock Based Compensation | 39.00 | 40.00 | - - | 81.00 | 93.00 | 142.00 | 226.00 | 305.00 | |
| Other | 2.00 | 1.00 | - - | -3.00 | 62.00 | 372.00 | 59.00 | -19.00 | |
| Highlighted metrics | |||||||||
| Free Cash Flow (FCF) | 33.00 | -389.00 | -436.00 | -490.00 | 1,959.00 | 13,336.00 | 4,581.00 | -3,825.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | -73.00 | -10,598.00 | 3,171.00 | 226.00 | 57.00 | 33.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - |